Possible pharmacologic glioma treatment in Drosophila model

Possible pharmacologic glioma treatment in Drosophila model

    Presenter(s)

    Luke Alan Bressler, Karishma Sanjay Gangwani, Catherine E Martini, Margarita Rosa Mendez, Isha Mishra, Kirti Snigdha, Jordan M Terschluse

    Description

    Glioma is a lethal brain cancer, and current treatment strategies have limited effects by extending life only by a few months. Thus, efforts should be made to discover better inhibitors of glioma growth. Ideally such inhibitors will suppress the progression of glioma by (a) inhibiting the underlying molecular pathways activated in glioma, or (b) prevent rapid proliferation of the glia and other cells that encompass the glioma tumor. We have developed a glioma model by co-activating PI3K and Ras/MAPK specifically in the Drosophila CNS glia. The Drosophila glioma cause the larval brain to appear enlarged due to rapid increase in the stem cells and their glial and neural progeny. These tumors cause the larvae to enter a prolonged larval phase, and eventually kill the organism. We are conducting a chemical screen using Tyrosine kinase inhibitors (Selleck Biochem.) in which we feed early third instar (72h old) larvae 10 or 300uM chemicals in DMSO and then see effects on glioma growth, and survival in mature third instar stage (120h old). Using these metrics, here we present data from our screen on B1-B11 of the library. Once we identify potential glioma inhibitors in the primary screens, we will validate them in secondary screens.

    Publication Date

    4-18-2018

    Project Designation

    Independent Research

    Primary Advisor

    Madhuri Kango-Singh

    Primary Advisor's Department

    Biology

    Keywords

    Stander Symposium project

    Possible pharmacologic glioma treatment in Drosophila model

    Share

    COinS